marked.bio

PARP1-selective inhibitor · small molecule

saruparib

4 active trials, targeting PARP1. Not approved for any biomarker on marked.bio yet.

Also known as AZD5305.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 4 5 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of saruparib.

  1. AstraZeneca 3

Trials

4 of 5 trials shown

  1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    Recruiting Phase 3 AstraZeneca Started 2025Primary completion 2033-03 NCT06952803

    saruparibabiraterone FDA EUprednisoneAndrogen Deprivation Therapy (ADT)

    …uparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    BRCA1/2 mutationProstate Cancer

  2. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    Recruiting Phase 3 AstraZeneca Started 2024Primary completion 2029-12 NCT06380751

    saruparibcamizestrantabemaciclibribociclibpalbociclibfulvestrantletrozoleanastrozoleExemestane

    Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2

    BRCA1/2 mutationAdvanced Breast Cancer

  3. Saruparib in HRDsig+ Solid Tumors

    Not yet recruiting Phase 2 Abramson Cancer Center at Penn Medicine Started 2026Primary completion 2029-11 NCT07832630

    saruparib

    Patients in Cohort A must also have a documented pathogenic germline or somatic variant in BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D or BARD1 as assessed by a CLIA certified laborator…

    BRCA1/2 mutationMalignant Neoplastic Disease (Disorder)

  4. Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

    Active, not recruiting Phase 1 AstraZeneca Started 2014Primary completion 2025-03 NCT02264678

    ceralasertibolaparib FDA EUdurvalumabsaruparibcarboplatin

    Module 5 Part B: known or suspected BRCA mutation, PALB2 mutation, RAD51C/D mutation or HRD positive status

    BRCA1/2 mutationAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer